Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries India Globalization Capital Inc (NY: IGC ) 0.4124 +0.0073 (+1.80%) Official Closing Price Updated: 8:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about India Globalization Capital Inc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research April 03, 2024 --News Direct-- Via News Direct IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer's Research April 02, 2024 Via Benzinga InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company March 27, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock March 26, 2024 From IGC Pharma Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Interim Results from Phase 2 Study Evaluating Treatment to Reduce Alzheimer’s Agitation March 21, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success March 20, 2024 IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability... Via Benzinga Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo March 20, 2024 IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. Via Benzinga InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) to Participate at Benzinga Virtual Healthcare Summit 2024 March 20, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation March 20, 2024 From IGC Pharma, Inc. Via Business Wire IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 March 20, 2024 From IGC Pharma, Inc. Via Business Wire Benzinga's 2024 Virtual Healthcare: What's Next In Health? March 19, 2024 The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... Via Benzinga IGC Pharma Advances In Alzheimer's Research From Pre-clinical Studies To Phase Two Trial With Its Novel Therapy Candidate IGC-AD1 March 19, 2024 --News Direct-- Via News Direct InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Names Healthcare Leader to Board of Directors March 13, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline March 12, 2024 From IGC Pharma, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session February 28, 2024 Via Benzinga InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports ‘Promising’ Results in Preclinical Studies Evaluating Drug Candidate for Alzheimer’s Treatment February 28, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model February 28, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Spotlighted in Ascendiant Equity Analyst Report February 23, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target February 23, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Releases Q3 2024 Financial Results, Reports Corporate Achievements February 20, 2024 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property IGC Pharma Announces Q3 2024 Earnings: Strategic Patent Achievements Propel Forward Amid Losses February 19, 2024 IGC Pharma's Q3 2024 results: Navigating financial dips with strategic patents in pain treatment and Alzheimer's therapy. Via Benzinga Topics Intellectual Property Exposures Intellectual Property IGC Pharma Reports Third Quarter Fiscal 2024 Results February 16, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data from Preclinical Studies Indicating Proprietary Drug Candidate Reduces Agitation in Alzheimer’s Mouse Model February 01, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model February 01, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing Proprietary Drug Candidate TGR-63 Reduces Plaque in Alzheimer’s January 23, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence Product Safety Why IGC Pharma Stock Is Moving Higher January 23, 2024 IGC Pharma highlighted data from a trial in which the group treated with TGR-63 showed a 78% and 85% reduction in the cortical and hippocampal amyloid load, respectively, reaffirming its potential to... Via Benzinga IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s January 23, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Activates ClinCloud in Phase 2b Alzheimer’s Trial January 17, 2024 Via Investor Brand Network Topics Artificial Intelligence Exposures Artificial Intelligence IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial January 17, 2024 From IGC Pharma, Inc. Via Business Wire InvestorNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives ‘Milestone’ Patent for Drug Formulation Used to Treat Agitation in Alzheimer’s December 19, 2023 Via Investor Brand Network Topics Artificial Intelligence Intellectual Property Exposures Artificial Intelligence Intellectual Property < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.